5466-33-1

Usage

Uses

Used in Medicinal Chemistry:
2-(2,4-dimethylphenyl)quinoline-4-carboxylic acid is used as a building block for the synthesis of various pharmaceuticals and bioactive compounds due to its versatile chemical properties and the presence of a quinoline core, which is common in many biologically active molecules.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 2-(2,4-dimethylphenyl)quinoline-4-carboxylic acid is used as a key intermediate for the development of new drugs, leveraging its potential to contribute to the creation of molecules with anti-malarial and anti-cancer properties.
Used in Bioactive Compounds Synthesis:
2-(2,4-dimethylphenyl)quinoline-4-carboxylic acid is utilized as a precursor in the synthesis of bioactive compounds, taking advantage of its structural features to enhance the biological activity of the resulting molecules.

InChI:InChI=1/C18H15NO2/c1-11-7-8-13(12(2)9-11)17-10-15(18(20)21)14-5-3-4-6-16(14)19-17/h3-10H,1-2H3,(H,20,21)

Upstream product

• 91-56-5 indole-2,3-dione 
• 89-74-7 2,4-dimethylacetophenone. 

Downstream Products

• 883526-18-9 2-(2,4-dimethyl-phenyl)-quinoline-4-carbonyl chloride 
• 76890-08-9 2-(2,4-dimethyl-phenyl)-quinoline 

Relevant academic research and scientific papers

Discovering novel chemical inhibitors of human cyclophilin A: Virtual screening, synthesis, and bioassay

Cyclophilin A (CypA) is a member of cyclophilins, a family of the highly homologous peptidyl prolyl cis-trans isomerases (PPIases), which can bind to cyclosporin A (CsA). CypA plays critical roles in various biological processes, including protein folding, assembly, transportation, regulation of neuron growth, and HIV replication. The discovery of CypA inhibitor is now of a great special interest in the treatment of immunological disorders. In this study, a series of novel small molecular CypA inhibitors have been discovered by using structure-based virtual screening in conjunction with chemical synthesis and bioassay. The SPECS_1 database containing 85,000 small molecular compounds was searched by virtual screening against the crystal structure of human CypA. After SPR-based binding affinity assay, 15 compounds were found to show binding affinities to CypA at submicro-molar or micro-molar level (compounds 1-15). Seven compounds were selected as the starting point for the further structure modification in considering binding activity, synthesis difficulty, and structure similarity. We thus synthesized 40 new small molecular compounds (1-6, 15, 16a-q, 17a-d, and 18a-l), and four of which (compounds 16b, 16h, 16k, and 18g) showed high CypA PPIase inhibition activities with IC50s of 2.5-6.2 μM. Pharmacological assay indicated that these four compounds demonstrated somewhat inhibition activities against the proliferation of spleen cells.